We are live on ! Find out more
TA

Tamarack Advisers Portfolio holdings

AUM $2.12M
1-Year Est. Return 58.09%
This Fund
S&P 500
This Quarter Est. Return
+7.2%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$183M
AUM Growth
+$19.9M
Cap. Flow
+$7.39M
Cap. Flow %
4.03%
Top 10 Hldgs %
71.1%
Holding
42
New
10
Increased
11
Reduced
9
Closed
10

Top Buys

Rank Stock Value
1
NXTM
NxStage Medical Inc.
NXTM
+$7.25M
2
NVCR icon
NovoCure
NVCR
+$6M
3
QDEL icon
QuidelOrtho
QDEL
+$4.9M
4
DGX icon
Quest Diagnostics
DGX
+$4.74M
5
MCK icon
McKesson
MCK
+$3.7M

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$17.5M
2
CVS icon
CVS Health
CVS
+$6.1M
3
SRCL
Stericycle Inc
SRCL
+$4.17M
4
STE icon
Steris
STE
+$4.01M
5
XRAY icon
Dentsply Sirona
XRAY
+$2.99M

Sector Composition

Rank Sector Weight
1 Healthcare 92.06%
2 Industrials 3.25%
3 Consumer Discretionary 2.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVCR icon
1
NovoCure
NVCR
$1.73B
$21.3M 11.63%
1,055,000
+311,446
+42% +$6M
MDRX
2
DELISTED
Veradigm Inc. Common Stock
MDRX
$20M 10.92%
1,375,000
-100,000
-7% -$1.39M
PCRX icon
3
Pacira BioSciences
PCRX
$1.04B
$14.4M 7.85%
315,000
+65,000
+26% +$2.58M
LH icon
4
Labcorp
LH
$25B
$12.8M 6.97%
93,120
+23,280
+33% +$3.08M
NUVA
5
DELISTED
NuVasive, Inc.
NUVA
$12.3M 6.72%
210,340
+50,340
+31% +$2.85M
MDT icon
6
Medtronic
MDT
$109B
$12.1M 6.61%
150,000
-15,000
-9% -$1.2M
QDEL icon
7
QuidelOrtho
QDEL
$1.14B
$11.7M 6.39%
270,000
+120,000
+80% +$4.9M
CORI
8
DELISTED
Corium International, Inc.
CORI
$9.71M 5.3%
1,010,000
+60,000
+6% +$640K
GILD icon
9
Gilead Sciences
GILD
$162B
$9.31M 5.08%
130,000
+5,000
+4% +$380K
NXTM
10
DELISTED
NxStage Medical Inc.
NXTM
$6.66M 3.64%
+275,000
New +$7.25M
NKTR icon
11
Nektar Therapeutics
NKTR
$2.39B
$6.27M 3.42%
7,000
-29,667
-81% -$17.5M
DGX icon
12
Quest Diagnostics
DGX
$25.7B
$4.92M 2.69%
+50,000
New +$4.74M
SRCL
13
DELISTED
Stericycle Inc
SRCL
$4.19M 2.29%
61,641
-61,359
-50% -$4.17M
HIND
14
Vyome Holdings
HIND
$14.9M
– –
0
– –
MCK icon
15
McKesson
MCK
$100B
$3.9M 2.13%
+25,000
New +$3.7M
ALKS icon
16
Alkermes
ALKS
$8.22B
$3.83M 2.09%
+70,000
New +$3.57M
SCI icon
17
Service Corp International
SCI
$11.7B
$3.73M 2.04%
+100,000
New +$3.58M
ATRC icon
18
AtriCure
ATRC
$1.92B
$3.19M 1.74%
175,000
+75,000
+75% +$1.49M
ADMS
19
DELISTED
Adamas Pharmaceuticals
ADMS
$3.14M 1.71%
+92,600
New +$2.59M
LNTH icon
20
Lantheus
LNTH
$6.49B
$3.08M 1.68%
150,437
+20,437
+16% +$416K
CORV
21
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$2.91M 1.59%
1,875,000
+125,000
+7% +$201K
ISEE
22
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$2.34M 1.28%
750,000
-25,000
-3% -$70.3K
STE icon
23
Steris
STE
$22.3B
$2.19M 1.19%
25,000
-45,000
-64% -$4.01M
STRM
24
DELISTED
Streamline Health Solutions
STRM
$1.77M 0.97%
70,000
+222
+0.3% +$5.1K
RCM
25
DELISTED
R1 RCM Inc. Common Stock
RCM
$1.76M 0.96%
400,000
-25,000
-6% -$97.8K
1
2

Similar funds

SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
LBC
Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
STC
Sarah T. Connolly $1.11M AUM 24.13% 1-Year Est. Return
GC
Gilfoyle & Co San Francisco, California $671K AUM
DU
Delphia (USA) Toronto, Ontario, Canada $445K AUM 28.82% 1-Year Est. Return

Tamarack Advisers's Q4 2017 Portfolio in Review

As of Q4 2017, Tamarack Advisers held 42 positions worth $183M, up 12% from $163M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Tamarack Advisers deployed $7.39M of net new capital in Q4 2017, opening 10 new positions and adding to 11 existing holdings. Its largest new stake was NxStage Medical Inc.: 275,000 shares worth $6.66M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 93% a quarter earlier, followed by Industrials and Consumer Discretionary.

On the sell side, the largest reduction was Nektar Therapeutics, an estimated $17.5M trimmed.

  • Tamarack Advisers's largest Q4 2017 buy was NxStage Medical Inc.: 275,000 shares worth $6.66M.
  • Tamarack Advisers added most to NovoCure in Q4 2017, an estimated $6M increase.
  • Tamarack Advisers's biggest Q4 2017 reduction was Nektar Therapeutics, cutting an estimated $17.5M.
  • Tamarack Advisers fully exited CVS Health in Q4 2017, selling an estimated $6.1M.
  • Tamarack Advisers's ten largest holdings make up 71% of its $183M portfolio in Q4 2017.
  • Tamarack Advisers opened 10 new positions and closed 10 in Q4 2017.
  • Tamarack Advisers's portfolio value rose 12% quarter-over-quarter to $183M.

Based on Tamarack Advisers's 13F filing for Q4 2017, filed 14 Feb 2018.